CarolRSchermerMDMPH, FACS
General Surgery • Oshkosh, WITrauma Surgery & Surgical Critical Care
Intensivist-Sound Physicians
Dr. Schermer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
855 N Westhaven Dr
Oshkosh, WI 54904Phone+1 920-303-8700
Education & Training
University of California Davis HealthFellowship, Surgical Critical Care, 1996 - 1997
University of New Mexico School of MedicineResidency, Surgery, 1991 - 1996- University of New Mexico School of MedicineClass of 1991
Certifications & Licensure
CA State Medical License 2012 - Present
IL State Medical License 2006 - 2026
NM State Medical License 1991 - 2025
WI State Medical License 2021 - 2025
NC State Medical License 2005 - 2006- American Board of Surgery Surgery
- American Board of Surgery Surgical Critical Care
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
Clinical Trials
- Effects of IV Chloride Content on Outcomes Start of enrollment: 2013 Sep 01
Publications & Presentations
PubMed
- 49 citationsEfficacy, safety, and tolerability of mirabegron in patients aged ≥65 yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (P...Adrian Wagg, David R. Staskin, Eli Engel, Sender Herschorn, Rita M Kristy
European Urology. 2020-02-01 - 13 citationsSafety and Tolerability Results from the PILLAR Study: A Phase IV, Double-Blind, Randomized, Placebo-Controlled Study of Mirabegron in Patients ≥ 65 years with Overact...Sender Herschorn, David R. Staskin, Carol R. Schermer, Rita M Kristy, Adrian Wagg
Drugs & Aging. 2020-09-01 - 10 citationsFactors Associated with Improvements in Patient-Reported Outcomes During Mirabegron or Antimuscarinic Treatment of Overactive Bladder Syndrome: A Registry Study (PERSP...Kevin V. Carlson, Eric S. Rovner, Kavita V. Nair, Anna S. Deal, Rita M Kristy
Advances in Therapy. 2019-06-20
Press Mentions
FDA Approves Supplemental New Drug Application for Myrbetriq® (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder SymptomsMay 7th, 2018
FDA Approves Supplemental New Drug Application for Myrbetriq (Mirabegron) for Use in Combination with Solifenacin Succinate for the Treatment of Overactive Bladder SymptomsAugust 29th, 2011
Grant Support
- Trauma Center Brief Alcohol Treatments And COST EffectivenesNational Institute On Alcohol Abuse And Alcoholism2006–2007
- Prevention Of DUI Recidivism After TraumaNational Center For Research Resources2004–2007
- Use Of Heparin For Thromboprophylaxis In TraumaNational Center For Research Resources2004–2005
- Prevention Of DUI Recidivism After TraumaNational Institute On Alcohol Abuse And Alcoholism2000–2004
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
